PURPOSE: The objectives of this prospective randomized study of consolidation therapy were to evaluate recurrence-free survival (RFS), @entity1349 ( @entity1349 ), and the morbidity of intraperitoneal (IP) chromic @entity1391 suspension (32P) therapy in @entity1 with @entity43 who have no detectable evidence of disease at the @entity1605 ( @entity1605 ) procedure after primary chemotherapy. @entity1 AND METHODS: In a multi-institution clinical cooperative trial, 202 eligible @entity1 with a negative @entity1605 were randomly selected to receive either 15 mCi IP 32P (n = 104) or @entity34 ( @entity34 ; n = 98). RESULTS: With a median follow-up of 63 months in living @entity1 , 68 @entity1 in the IP 32P group (65%) and 63 @entity1 in the @entity34 group (64%) have developed @entity5 recurrence. The relative risk of recurrence is 0.90 (IP 32P to @entity34 ) (90% confidence interval [CI], 0.68 to 1.19). The 5-year RFS rate is 42% and 36% for the IP 32P and @entity34 groups, respectively; the difference is not statistically significant (log-rank test, P =.27). There was no statistically significant difference in @entity1349 (P =.19). The relative risk of death is 0.85 (IP 32P to @entity34 ) (90% CI, 0.62 to 1.16). Sixteen @entity1 (8%) experienced grade 3 or 4 adverse effects, with eight in each respective group. CONCLUSION: Intraperitoneal chromic @entity1391 did not decrease the risk of relapse or improve survival for @entity1 with @entity43 after a negative @entity1605 . Despite complete pathologic remission at @entity1605 after initial surgery and @entity902 -based chemotherapy, 61% of @entity43 @entity1 had @entity5 recurrence within 5 years of negative @entity1605 . This indicates a need for more effective initial therapy and further studies of consolidation therapy.

Intraperitoneal radioactive phosphorus (32P) versus observation after negative XXXX for @entity43 : a randomized trial of the Gynecologic Oncology Group.

@entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS'] @entity43 :: ('MESH:D010051', 'Disease') :: ['stage III epithelial ovarian carcinoma', 'stage III epithelial ovarian cancer', 'stage III ovarian cancer'] @entity1605 :: ('OMIM:217000', 'Disease') :: ['SLL', 'second-look laparotomy'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1391 :: ('CHEBI:26020', 'Chemical') :: ['phosphate'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival'] @entity34 :: ('MESH:D016609', 'Disease') :: ['NFT', 'no further therapy']
@entity1605 :: (OMIM:217000,Disease) :: ['second-look laparotomy']
